FKBP51 plays a significant role in tauopathies, particularly AD, by influencing tau protein’s stability, aggregation, and neurotoxicity. The increase in FKBP51 levels with age and in AD, potentially due to changes in DNA methylation. This evidence concerns the gene MAPT and Alzheimer disease.